SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, WA: IASP Press; 1994.
  • 2
    Bouhassira D. Definition and classification of neuropathic pain [in French]. Presse Med. 2008; 37: 311314.
  • 3
    Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain. 1999; (Suppl 6): S141S147.
  • 4
    Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004; 140: 441451.
  • 5
    Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008; 9: 883891.
  • 6
    Tunks ER, Crook J, Weir R. Epidemiology of chronic pain with psychological comorbidity: prevalence, risk, course, and prognosis. Can J Psychiatry. 2008; 53: 224235.
  • 7
    McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003; 106: 127133.
  • 8
    McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004; 111: 7783.
  • 9
    Von Korff M, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. Pain. 2005; 113: 331339.
  • 10
    Kirmayer LJ, Robbins JM, Dworkind M, et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry. 1993; 150: 734741.
  • 11
    Hudson JL, Hudson MS, Pliner LF, et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry. 1985; 142: 441446.
  • 12
    Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociceptive: implications for mechanisms of pain. Pain. 2007; 131: 243257.
  • 13
    Berta T, Poirot O, Pertin M, et al. Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. Mol Cell Neurosci. 2008; 37: 196208.
  • 14
    Pertin M, Ji RR, Berta T, et al. Upregulation of the voltage-gated sodium channel beta 2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci. 2005; 25: 1097010980.
  • 15
    Lai J, Porreca F, Hunter JC, Gold MS. Voltage gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol. 2004; 44: 371397.
  • 16
    Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993; 52: 259285.
  • 17
    Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicentre trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50: 29742984.
  • 18
    Crofford LJ. Pharmaceutical treatment options for fibromyalgia. Curr Rheumatol Rep. 2004; 6: 274280.
  • 19
    Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983; 306: 686688.
  • 20
    Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain. 2002; 96: 365373.
  • 21
    Sawnyok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001; 26: 2129.
  • 22
    Gray AM, Pache DM, Sewell RD. Do alpha2-adrenoceptors play a role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol. 1999; 378: 161168.
  • 23
    Eschalier A, Montastruc JL, Devoize JL, Rigal F, Gaillard-Plaza G, Pechadre JC. Influence of naloxone and methysergide on the analgesic effect of clomipramine in rats. Eur J Pharmacol. 1981; 74: 17.
  • 24
    Yokogawa F, Kiuchi Y, Ishikawa Y, et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg. 2002; 95: 163168.
  • 25
    Mico JA, Gibert-Rahola J, Casas J, Rojas O, Serrano MI, Serrano JS. Implication of b1- and b2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants. Eur Neuropsychopharmacol. 1997; 7: 139145.
  • 26
    Cai Z, McCaslin PP. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainite- and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol. 1992; 219: 5357.
  • 27
    Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996; 29: 2326.
  • 28
    Ogata N, Yoshii M, Narahashi T. Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res. 1989; 476: 140144.
  • 29
    Sudoh Y, Cahoon EE, Gerner P, et al. Tricyclic antidepressants as long-acting local anesthetics. Pain. 2003; 103: 4955.
  • 30
    Antkiewicz-Michaluk L, Romanska I, Michaluk J, Vetulani J. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology (Berl). 1991; 105: 269274.
  • 31
    Galeotti N, Ghelardini C, Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology. 2001; 40: 7584.
  • 32
    Sawynok J, Reid AR, Liu XJ, Parkinson FE. Amitriptyline enhances extracellular tissue levels of adenosine in the rat hindpaw and inhibits adenosine uptake. Eur J Pharmacol. 2005; 518: 116122.
  • 33
    McCarson KE, Duric V, Reisman SA, Winter M, Enna SJ. GABAB receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. Brain Res. 2006; 1068: 109117.
  • 34
    Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995; 332: 16851690.
  • 35
    Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol. 1998; 124: 669674.
  • 36
    Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999; 42: 25612568.
  • 37
    Ignatowski TA, Sud R, Reynolds JL, Knight PR, Spengler RN. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-a (TNF). Neuropharmacology. 2005; 48: 448460.
  • 38
    Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs 2008; 68: (18): 261132.
  • 39
    Perrot S, Javier RM, Marty M, Le Jeunne C, Laroche F. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford). 2008; 47: 11171123.
  • 40
    Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998; 51: 16821688.
  • 41
    Mercadante S, Arcuri E, Tirelli W, et al. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumor. 2002; 88: 239242.
  • 42
    Robinson LR, Czerniecki JM, Ehde DM, et al. Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Arch Phys Med Rehabil. 2004; 85: 16.
  • 43
    Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987; 37: 589596.
  • 44
    Max MB. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991; 45: 39.
  • 45
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; 4: CD005454.
  • 46
    Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med. 2002; 162: 1924.
  • 47
    Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992; 49: 205202.
  • 48
    Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial. Neurology. 2002; 59: 10151021.
  • 49
    Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized controlled trial. Neurology. 2003; 60: 12841289.
  • 50
    Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992; 326: 12501256.
  • 51
    Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004; 110: 697706.
  • 52
    Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005; 116: 109118.
  • 53
    Wernicke JF, Pritchett YL, D'Souza DM, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67: 14111420.
  • 54
    Norregard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled study of citalopram in the treatment of fibromyalgia. Pain. 1995; 61: 445449.
  • 55
    Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. Clin Exp Rheumatol. 2001; 19: 697702.
  • 56
    Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002; 112: 191197.
  • 57
    Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009; 36: 398409.
  • 58
    O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000; 15: 659666.
  • 59
    Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000; 41: 490499.
  • 60
    Katz J, Pennella-Vaughan J, Hetzel RD, et al. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain. 2005; 6: 656661.
  • 61
    Staiger TO, Gaster B, Sullivan MD, et al. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003; 28: 25402545.
  • 62
    Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res. 1976; 4: 2840.
  • 63
    Ash G, Dickens CM, Creed FH, Jayson MI, Tomenson B. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology. 1999; 38: 959967.
  • 64
    Koh WH, Pande I, Samuels A, Jones SD, Calin A. Low-dose amitriptyline in ankylosing spondylitis: a short-term, double-blind, placebo-controlled study. J Rheumatol. 1997; 4: 21582161.
  • 65
    Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacological properties and the therapeutic use in chronic pain states. Drugs Aging. 1996; 8: 459476.
  • 66
    Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995; 45(Suppl 9): 1725.
  • 67
    Attal N, Cruccua G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006; 13: 11531169.
  • 68
    Leijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain. 1989; 36: 2736.
  • 69
    Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005; 118: 289305.
  • 70
    Goldenberg DL, Felson DT, Dinerman H. A randomised, controlled trial of amitriptyline and naproxene in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986; 29: 13711377.
  • 71
    Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blinded, placebo-controlled study. Arthritis Rheum. 1986; 29: 655659.
  • 72
    Bibolotti E, Borghi C, Pasculli E, et al. The management of fibrositis. A double-blind comparison of maprotiline (Ludiomil) clorimipramine and placebo. Clin Trials J. 1986; 23: 269280.
  • 73
    Caruso I, Puttini Sarzi PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1987; 15: 154159.
  • 74
    Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988; 31: 15351542.
  • 75
    Hamaty D, Valentine JL, Howard R, Howard CW, Wakefield V, Patten MS. The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol. 1989; 19(Suppl): 164168.
  • 76
    Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol. 1989; 19(Suppl): 98103.
  • 77
    Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol. 1989; 19(Suppl): 140143.
  • 78
    Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991; 18: 452454.
  • 79
    Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharm Res. 1992;XII: 99102.
  • 80
    Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum. 1994; 37: 3240.
  • 81
    Cantini F, Bellandi F, Niccoli L, Di Munno O. Fluoxetina associata a ciclobenzaprina nel trattamento della fibromialgia. Minerva Med. 1994; 85: 97100.
  • 82
    Goldenberg D, Mayskiy M, Mossey C, Ruthaser R, Schmid C. A randomized, doubleblind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996; 39: 18521859.
  • 83
    Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskel Pain. 1996; 4: 3747.
  • 84
    Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998; 37: 12791286.
  • 85
    Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics. 2000; 41: 104113.
  • 86
    Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians Clinical practice guideline. Ann Intern Med. 2007; 147: 505514.
  • 87
    Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. Pain Symptom Manage. 2004; 28: 7295.
  • 88
    Stein D, Peri T, Edelstein E, Elizur A, Floman Y. The efficacy of amitriptyline and acetaminophen in the management of acute low back pain. Psychosomatics. 1996; 36: 6370.
  • 89
    Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998; 76: 287296.
  • 90
    Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999; 83: 137145.
  • 91
    Lin EH, Katon W, Von Korff M, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. J Am Med Assoc. 2003; 290: 24282429.
  • 92
    McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia. 1993; 48: 281285.
  • 93
    Wheatley D. Antidepressants in elderly arthritics. Practitioner. 1986; 230: 477481.
  • 94
    Tomkins GE, Jackson JL, O'Malley PG, et al. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med. 2001; 111: 5463.
  • 95
    Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006; 27: 410415.
  • 96
    Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging. 2006; 23: 461489.
  • 97
    Anderberg UA, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia—a randomised, double-blind, placebo-controlled study. Eur J Pain. 2000; 4: 2735.
  • 98
    Geller SA. Treatment of fibrositis with fluoxetine hydrochloride (Prozac). Am J Med. 1989; 87: 594595.
  • 99
    Cortet B, Houvenagel E, Forzy G, Vincent G, Delcambre B. Evaluation of the effectiveness of serotonin (fluoxetine hydrochloride) treatment. Open study in fibromyalgia. Rev Rhum Mal Osteoartic. 1992; 59: 497500.
  • 100
    Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994; 23: 255259.
  • 101
    Ataoglu S, Ataoglu A, Erdoan F, Sarac J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci. 1997; 27: 535539.
  • 102
    Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled-release paroxetine in fibromyalgia. Am J Med. 2007; 120: 448454.
  • 103
    Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990; 42: 135144.
  • 104
    Ciaramella A, Grosso S, Poli P. Fluoxetine versus fluvoxamine for treatment of chronic pain [in Italian]. Minerva Anestesiol. 2000; 66: 5561.
  • 105
    Maina G, Vitalucci A, Gandolfo S, et al. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry. 2002; 63: 3843.
  • 106
    Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992; 52: 547552.
  • 107
    Moja PL, Cusi C, Sterzi RR, et al. Selective serotonin reuptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005; 3: CD002919.
  • 108
    Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care. 2000; 23: 17101711.
  • 109
    Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother. 2001; 35: 557559.
  • 110
    Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003; 37: 15611565.
  • 111
    Dwight MM, Arnold LD, O'Brien H, Metzger R, Morris-Park E, Keck PE. An open trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 1998; 39: 1417.
  • 112
    Arnold LM, Rosen A, Pritchett YL, et al. A randomised, double-blind, placebo controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005; 119: 515.
  • 113
    Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008; 30: 19882004.
  • 114
    Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005; 45: 144152.
  • 115
    Bulut S, Berilgen MS, Barar A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004; 107: 4448.
  • 116
    Pakulska W, Czarnecka E. Influence of mianserin on the antinociceptive effect of morphine, metamizol and indomethacin in mice. Pharmacol Res. 2002; 46: 415423.
  • 117
    Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol. 1992; 43: 251255.
  • 118
    Zhu J, Wei X, Feng X, Song J, Hu Y, Xu J. Repeated administration of mirtazapine inhibits development of hyperalgesia/allo-dynia and activation of NF-kappaB in a rat model of neuropathic pain. Neurosci Lett. 2008; 433: 3337.
  • 119
    Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin. 2006; 22: 257264.
  • 120
    Pick CG, Paul D, Eison MS, Pasternak GW. Potentiation of opioids analgesia by the antidepressant nefazodone. Eur J Pharmacol. 1992; 211: 375381.
  • 121
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman GA, Rall TTW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. Vol. 8. New York: Pergamon Press; 1990: 383435.
  • 122
    Glassman AH, Bigger JT. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch Gen Psychiatry. 1981; 36: 815819.
  • 123
    Eschalier A, Ardid D, Dubray C. Tricyclic and other antidepressants as analgesics. In: Sawynok J, Cowan A, eds. Novel Aspects of Pain Management: Opioids and Beyond. New York: Wiley-Liss; 1999;303319.
  • 124
    McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain. 1996; 68: 217227.
  • 125
    Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin in chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil. 2007; 88: 15471560.
  • 126
    Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther. 1998; 284: 208214.
  • 127
    Harrigan RA, Brady WJ. ECG abnormalities in tricyclic anti-depressant ingestion. Am J Emerg Med. 1999; 17: 387393.
  • 128
    Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J. 1996; 155: 519527.
  • 129
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352: 11121120.
  • 130
    Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010; 85: S3S14.
  • 131
    Rosenzweig TM, Thomas TM. An update on fibromyalgia syndrome: the multimodal therapeutic approach. Am J Lifestyle Med. 2009; 3: 226237.
  • 132
    Practice Guidelines for Chronic Pain Management. An updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology. 2010; 112: 810833.